MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 461522 | Name: Trandolaprilat
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Trandolaprilat is a non-sulfhydryl angiotensin-converting enzyme inhibitor.

Chemical Structure

Trandolaprilat
Trandolaprilat
CAS#87679-71-8

Theoretical Analysis

MedKoo Cat#: 461522

Name: Trandolaprilat

CAS#: 87679-71-8

Chemical Formula: C22H30N2O5

Exact Mass: 402.2155

Molecular Weight: 402.49

Elemental Analysis: C, 65.65; H, 7.51; N, 6.96; O, 19.87

Price and Availability

Size Price Availability Quantity
2mg USD 400.00 2 Weeks
25mg USD 2,450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Trandolaprilat; Trandolaprilate; RU 44403; RU44403; RU-44403; Trandolapril diacid, Trandolapril Related Compound E,
IUPAC/Chemical Name
(2S,3aR,7aS)-1-(((S)-1-carboxy-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic acid
InChi Key
AHYHTSYNOHNUSH-HXFGRODQSA-N
InChi Code
InChI=1S/C22H30N2O5/c1-14(23-17(21(26)27)12-11-15-7-3-2-4-8-15)20(25)24-18-10-6-5-9-16(18)13-19(24)22(28)29/h2-4,7-8,14,16-19,23H,5-6,9-13H2,1H3,(H,26,27)(H,28,29)/t14-,16+,17-,18-,19-/m0/s1
SMILES Code
O=C([C@H]1N(C([C@H](C)N[C@H](C(O)=O)CCC2=CC=CC=C2)=O)[C@@]3([H])CCCC[C@]3([H])C1)O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 402.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wang X, Her L, Xiao J, Shi J, Wu AH, Bleske BE, Zhu HJ. Impact of carboxylesterase 1 genetic polymorphism on trandolapril activation in human liver and the pharmacokinetics and pharmacodynamics in healthy volunteers. Clin Transl Sci. 2021 Jul;14(4):1380-1389. doi: 10.1111/cts.12989. Epub 2021 Mar 4. PMID: 33660934; PMCID: PMC8301577. 2: Alfaro S, Navarro-Retamal C, Caballero J. Transforming Non-Selective Angiotensin-Converting Enzyme Inhibitors in C- and N-domain Selective Inhibitors by Using Computational Tools. Mini Rev Med Chem. 2020;20(14):1436-1446. doi: 10.2174/1389557520666191224113830. PMID: 31889494. 3: Owczarczyk-Saczonek A, Znajewska-Pander A, Owczarek W, Maciejewska-Radomska A, Placek W. Clinicopathologic retrospective analysis of annular pustular psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2018 Dec;27(4):215-219. PMID: 30564836. 4: Magdy R, El-Khatib AH, Hemdan A, Elaziz OA, Farouk M, Linscheid MW. Comparative pharmacokinetics of trandolapril, its active metabolite, and verapamil in human plasma of Egyptian population using HPLC-MS/MS. Drug Test Anal. 2018 Jan 10. doi: 10.1002/dta.2357. Epub ahead of print. PMID: 29319234. 5: Li X, Liu C, Wu M, Zhang H, Sun Y, Cheng L, Chen H, Liu C, Yang L, Zhang Q, Cao Y, Gu J, Ding Y. Pharmacokinetics, Pharmacodynamics, and Tolerability of Single and Multiple Doses of Trandolapril, an Effective Angiotensin-Converting Enzyme Inhibitor, in Healthy Chinese Subjects. Eur J Drug Metab Pharmacokinet. 2016 Aug;41(4):373-84. doi: 10.1007/s13318-015-0277-2. PMID: 25864194. 6: Gupta VK, Jain R, Lukram O, Agarwal S, Dwivedi A. Simultaneous determination of ramipril, ramiprilat and telmisartan in human plasma using liquid chromatography tandem mass spectrometry. Talanta. 2011 Jan 15;83(3):709-16. doi: 10.1016/j.talanta.2010.10.011. Epub 2010 Nov 18. PMID: 21147310. 7: Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol. 2009 Apr 1;77(7):1266-72. doi: 10.1016/j.bcp.2008.12.017. Epub 2009 Jan 6. PMID: 19185566. 8: Ceconi C, Francolini G, Olivares A, Comini L, Bachetti T, Ferrari R. Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. Eur J Pharmacol. 2007 Dec 22;577(1-3):1-6. doi: 10.1016/j.ejphar.2007.07.061. Epub 2007 Aug 3. PMID: 17716647. 9: Nirogi RV, Kandikere VN, Shrivastava W, Mudigonda K. Quantification of trandolapril and its metabolite trandolaprilat in human plasma by liquid chromatography/tandem mass spectrometry using solid-phase extraction. Rapid Commun Mass Spectrom. 2006;20(24):3709-16. doi: 10.1002/rcm.2794. PMID: 17117442. 10: Naito M, Kawashima A, Akiba T, Takanashi M, Nihei H. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol. 2003 Sep-Oct;23(5):287-93. doi: 10.1159/000072705. Epub 2003 Jul 31. PMID: 12897465. 11: Guay DR. Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther. 2003 Mar;25(3):713-75. doi: 10.1016/s0149-2918(03)80107-8. PMID: 12852701. 12: Hayase N, Satomi M, Hara A, Awaya T, Shimizu K, Matsubara K. Protective effects of quinaprilat and trandolaprilat, active metabolites of quinapril and trandolapril, on hemolysis induced by lysophosphatidylcholine in human erythrocytes. Biol Pharm Bull. 2003 May;26(5):712-6. doi: 10.1248/bpb.26.712. PMID: 12736518. 13: Coca A, Rabasseda X. Trandolapril in left ventricular dysfunction after myocardial infarction: focus on the TRACE study. Drugs Today (Barc). 2003 Jan;39(1):5-18. doi: 10.1358/dot.2003.39.1.799429. PMID: 12669106. 14: Shionoiri H, Takasaki I, Minamisawa K, Ishizuka H, Konno K, Naganuma H, Sasahara K, Kawahara Y. Trandolaprilat, an angiotensin-converting enzyme inhibitor, is not excreted in bile via an ATP-dependent active transporter (cMOAT). Hypertens Res. 2001 May;24(3):235-40. doi: 10.1291/hypres.24.235. PMID: 11409646. 15: Okumura H, Nishimura E, Kariya S, Ohtani M, Uchino K, Fukatsu T, Odanaka J, Takahashi T, Watanabe K, Itoh T, Hashiguchi M, Echizen H, Rikihisa T. [No relation between angiotensin-converting enzyme (ACE) inhibitor-induced cough and ACE gene polymorphism, plasma bradykinin, substance P and ACE inhibitor concentration in Japanese patients]. Yakugaku Zasshi. 2001 Mar;121(3):253-7. Japanese. doi: 10.1248/yakushi.121.253. PMID: 11265121. 16: Berthold H, Just A, Kirchheim HR, Ehmke H. Interaction between nitric oxide and endogenous vasoconstrictors in control of renal blood flow. Hypertension. 1999 Dec;34(6):1254-8. doi: 10.1161/01.hyp.34.6.1254. PMID: 10601127. 17: Berthold H, Münter K, Just A, Kirchheim HR, Ehmke H. Contribution of endothelin to renal vascular tone and autoregulation in the conscious dog. Am J Physiol. 1999 Mar;276(3):F417-24. doi: 10.1152/ajprenal.1999.276.3.F417. PMID: 10070165. 18: Houard X, Williams TA, Michaud A, Dani P, Isaac RE, Shirras AD, Coates D, Corvol P. The Drosophila melanogaster-related angiotensin-I-converting enzymes Acer and Ance--distinct enzymic characteristics and alternative expression during pupal development. Eur J Biochem. 1998 Nov 1;257(3):599-606. doi: 10.1046/j.1432-1327.1998.2570599.x. PMID: 9839949. 19: Peters DC, Noble S, Plosker GL. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 1998 Nov;56(5):871-93. doi: 10.2165/00003495-199856050-00014. PMID: 9829159. 20: Weir MR, Saunders E. Renin status does not predict the anti-hypertensive response to angiotensin-converting enzyme inhibition in African-Americans. Trandolapril Multicenter Study Group. J Hum Hypertens. 1998 Mar;12(3):189-94. doi: 10.1038/sj.jhh.1000578. PMID: 9579769.